

Correction: Viewpoint on anifrolumab in patients with systemic lupus erythematosus and a high unmet need in clinical practice

Tanaka Y. Viewpoint on anifrolumab in patients with systemic lupus erythematosus and a high unmet need in clinical practice. *RMD Open* 2023;9:e003270. doi: 10.1136/rmdopen-2023-003270

Updates have been made to the 2nd paragraph under the following section: *Patients with moderate to severe SLE who are unable to achieve at least LLDAS with existing SoC treatments.*

ORIGINAL PARAGRAPH

In a post hoc analysis of the pooled TULIP-1/TULIP-2 trials, 15.3% of anifrolumab-treated patients (300 mg every 4 weeks (Q4W)) achieved DORIS remission at Week 52, compared with 7.6% of patients treated with placebo (odds ratio (OR) (95% CI): 2.2 (1.4 to 3.6), $p=0.0013$). DORIS remission was achieved by significantly more patients in the anifrolumab group compared with the placebo group starting at Week 32, suggesting an earlier attainment of DORIS remission with anifrolumab treatment.

REVISED PARAGRAPH

In a post hoc analysis of the pooled TULIP-1/TULIP-2 trials, 15.3% of anifrolumab-treated patients (300 mg every 4 weeks (Q4W)) achieved DORIS remission at Week 52, compared with 6.6% of patients treated with placebo (odds ratio (OR) (95% CI): 2.6 (1.6 to 4.3), $p=0.0002$). DORIS remission was achieved by significantly more patients in the anifrolumab group compared with the placebo group starting at Week 32, suggesting an earlier attainment of DORIS remission with anifrolumab treatment.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

RMD Open 2024;10:e003270corr1. doi:10.1136/rmdopen-2023-003270corr1

